<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Tacrolimus (topical): Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Tacrolimus (topical): Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Tacrolimus (topical): Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9921" href="/d/html/9921.html" rel="external">see "Tacrolimus (topical): Drug information"</a> and <a class="drug drug_patient" data-topicid="12309" href="/d/html/12309.html" rel="external">see "Tacrolimus (topical): Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F9559507"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Malignancy:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Although a causal relationship has not been established, rare cases of malignancy (ie, skin cancer and lymphoma) have been reported in patients treated with topical calcineurin inhibitors, including tacrolimus ointment. Avoid continuous long-term use of topical calcineurin inhibitors, including tacrolimus ointment, in any age group, and limit application to areas of involvement with atopic dermatitis.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Pediatrics:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus ointment is not indicated for use in children younger than 2 years of age. Only tacrolimus 0.03% ointment is indicated for use in children 2 to 15 years of age.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F9559514"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Protopic [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52870372"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Protopic</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F54317275"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Calcineurin Inhibitor</span>;</li>
<li>
<span class="list-set-name">Immunosuppressant Agent</span>;</li>
<li>
<span class="list-set-name">Topical Skin Product</span></li></ul></div>
<div class="block dop drugH1Div" id="F9564226"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d8ecd230-ce3b-46da-85b5-ab9bafc77949">Atopic dermatitis, moderate to severe</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis, moderate to severe: Note:</b> Discontinue use when symptoms have cleared. If no improvement occurs within 6 weeks, patients should be reexamined to confirm diagnosis. Topical:</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment 0.03%: Children ≥2 years and Adolescents: Apply a thin layer to affected area twice daily; rub in gently and completely</p>
<p style="text-indent:-2em;margin-left:4em;">Ointment 0.1%: Adolescents ≥16 years: Apply a thin layer of 0.1% ointment to affected area twice daily; rub in gently and completely</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51160276"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block dohp drugH1Div" id="F51160277"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doa drugH1Div" id="F9564227"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9921" href="/d/html/9921.html" rel="external">see "Tacrolimus (topical): Drug information"</a>)</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b0eddb2b-0c7c-4191-bc31-11963bda3146">Allergic contact dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Allergic contact dermatitis (alternative agent) (off-label use): Topical:</b> Apply a thin layer of 0.1% ointment to the affected area(s) twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16781290','lexi-content-ref-25070257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16781290','lexi-content-ref-25070257'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c67e9e2b-6dad-418d-9ecc-84f4de0f5978">Atopic dermatitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Atopic dermatitis (moderate to severe):</b>
<b>Topical:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment:</i> Apply thin layer of 0.03% or 0.1% ointment to affected area twice daily; rub in gently and completely. Discontinue use when symptoms have cleared. If no improvement within 6 weeks, patients should be re-examined to confirm diagnosis.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance therapy (off-label use): </i>Apply one application (thin layer of 0.03% or 0.1% ointment) to areas usually affected twice daily twice a week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23374261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23374261'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a52f4bde-14a6-4ccf-a8aa-ca6c993b1483">Oral lichen planus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral lichen planus (off-label use): Topical:</b> Apply thin layer of 0.1% ointment to affected area(s) up to 4 times daily; the treatment period in clinical trials ranged from 4 to 6 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18269664','lexi-content-ref-16710580','lexi-content-ref-18230389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18269664','lexi-content-ref-16710580','lexi-content-ref-18230389'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="9c51dc6e-ca0a-48cc-bfad-6cb5d9403c14">Psoriasis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Psoriasis</b> (<b>intertriginous and facial)</b>
<b> (off-label use): Topical:</b> Apply thin layer of 0.1% ointment to affected area twice daily; the treatment period in clinical trials was 6 to 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32738429','lexi-content-ref-15523350','lexi-content-ref-31100992']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32738429','lexi-content-ref-15523350','lexi-content-ref-31100992'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="399db946-8e39-4223-8f9d-c83ef45d608d">Pyoderma gangrenosum</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pyoderma gangrenosum (refractory) (off-label use): Topical:</b> Apply thin layer of 0.1% ointment to affected area once daily. May taper to 0.03% ointment once daily after improvement is evident following several weeks of initial therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30252999','lexi-content-ref-20855912','lexi-content-ref-15149540']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30252999','lexi-content-ref-20855912','lexi-content-ref-15149540'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="256e3f8c-30ca-421e-8e2c-dd72c6311be9">Vitiligo</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Vitiligo (primarily the head and neck region</b>
<b>) (off-label use): Topical:</b> Apply thin layer of 0.1% ointment to affected area twice daily; reassess every 3 to 6 months for adequate response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160061','lexi-content-ref-22860621','lexi-content-ref-20831696','lexi-content-ref-19496898']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160061','lexi-content-ref-22860621','lexi-content-ref-20831696','lexi-content-ref-19496898'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990323"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block doha drugH1Div" id="F50987665"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>
<div class="block adr drugH1Div" id="F9559547"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. As reported in children and adults, unless otherwise noted. Frequency not always defined.</p>
<p style="text-indent:-2em;margin-left:2em;">Cardiovascular: Peripheral edema (adults 3% to 4%), hypertension (adults 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Central nervous system: Headache (adults 19% to 20%), tingling of skin (2% to 8%), hyperesthesia (adults 3% to 7%), insomnia (adults 4%), paresthesia (adults 3%), depression (adults 2%), pain (1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Dermatologic: Burning sensation of skin (43% to 58%), pruritus (41% to 46%), erythema (25% to 28%), skin infection (adults 12%), acne vulgaris (adults 4% to 7%), urticaria (adults 3% to 6%), folliculitis (2% to 6%), skin rash (adults 2% to 5%), dermatological disease (children 4%), vesiculobullous dermatitis (children 4%), contact dermatitis (3% to 4%), pustular rash (adults 2% to 4%), contact eczema herpeticum (children 2%), fungal dermatitis (adults 1% to 2%), sunburn (adults 1% to 2%), alopecia (adults 1%), xeroderma (children 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Gastrointestinal: Diarrhea (3% to 5%), dyspepsia (adults 1% to 4%), abdominal pain (children 3%), gastroenteritis (adults 2%), vomiting (adults 1%), nausea (children 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Genitourinary: Dysmenorrhea (adults 4%), urinary tract infection (adults 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Hematologic &amp; oncologic: Lymphadenopathy (children 3%), malignant lymphoma, malignant neoplasm of skin</p>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity: Hypersensitivity reaction (adults 6% to 12%)</p>
<p style="text-indent:-2em;margin-left:2em;">Infection: Herpes zoster (1% to 5%), varicella zoster infection (1% to 5%), infection (adults 1% to 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Neuromuscular &amp; skeletal: Myalgia (adults 2% to 3%), weakness (adults 2% to 3%), arthralgia (adults 1% to 3%), back pain (adults 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Ocular: Conjunctivitis (adults 2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Otic: Otitis media (children 12%), otalgia (children 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Respiratory: Flu-like symptoms (23% to 31%), increased cough (children 18%), asthma (adults 6%), rhinitis (children 6%), pharyngitis (adults 4%), sinusitis (adults 2% to 4%), bronchitis (adults 2%), pneumonia (adults 1%)</p>
<p style="text-indent:-2em;margin-left:2em;">Miscellaneous: Fever (children 21%), allergic reaction (4% to 12%), alcohol intolerance (adults 3% to 7%), accidental injury (6%), cyst (adults 1% to 3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports (Limited to important or life-threatening): Abnormality in thinking, abscess, acne rosacea, acute renal failure, aggravated tooth caries, anaphylactoid reaction, anemia, anorexia, anxiety, application site edema, arthritis, arthropathy, basal cell carcinoma, benign neoplasm (breast), blepharitis, bone disease, bursitis, candidiasis, cataract, chest pain, chills, colitis, conjunctival edema, constipation, cutaneous candidiasis, cystitis, dehydration, dermal ulcer, diaphoresis, dizziness, dry nose, dysgeusia, dyspnea, ear disease, ecchymoses, edema, epistaxis, eye pain, furunculosis, gastritis, gastrointestinal disease, heart valve disease, hernia, hyperbilirubinemia, hypercholesterolemia, hypertonia, hypothyroidism, impetigo (bullous), laryngitis, leukoderma, malaise, malignant lymphoma, malignant melanoma, migraine, muscle cramps, nail disease, neck pain, neoplasm (benign), oral candidiasis, oral mucosa ulcer, osteoarthritis, osteomyelitis, otitis externa, pulmonary disease, rectal disease, renal insufficiency, seborrhea, seizure, septicemia, skin carcinoma, skin discoloration, skin hypertrophy, skin photosensitivity, squamous cell carcinoma, stomatitis, syncope, tachycardia, tendinopathy, unintended pregnancy, vaginitis, vasodilation, vertigo, visual disturbance, vulvovaginal candidiasis, xerophthalmia, xerostomia</p></div>
<div class="block coi drugH1Div" id="F9559539"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to tacrolimus or any component of the formulation</p></div>
<div class="block war drugH1Div" id="F9559540"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse events:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Infection: Do not apply to areas of active bacterial or viral infection; infections at the treatment site should be cleared prior to therapy. Patients with atopic dermatitis are predisposed to skin infections, and tacrolimus therapy has been associated with risk of developing eczema herpeticum, varicella zoster, and herpes simplex.</p>
<p style="text-indent:-2em;margin-left:4em;">• Lymphadenopathy: May be associated with development of lymphadenopathy; possible infectious causes should be investigated. Discontinue use in patients with unknown cause of lymphadenopathy or acute infectious mononucleosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Malignancy: Avoid use on malignant or premalignant skin conditions (eg, cutaneous T-cell lymphoma). Limit sun and ultraviolet light exposure; use appropriate sun protection.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal failure: Acute renal failure has been observed (rarely) with topical use.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Immunosuppression: Should not be used in immunocompromised patients. Safety and efficacy have not been evaluated.</p>
<p style="text-indent:-2em;margin-left:4em;">• Skin diseases with altered absorption: Not recommended for use in patients with skin disease which may increase systemic absorption (eg, Netherton's syndrome).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: <b>[US Boxed Warning] Use in children &lt;2 years of age is not recommended, only the 0.03% ointment should be used in children ages 2 to 15 years.</b></p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Topical calcineurin agents are considered second-line therapies in the treatment of atopic dermatitis/eczema, and should be limited to use in patients who have failed treatment with other therapies. Safety not established in patients with generalized erythroderma. If atopic dermatitis is not improved in &lt;6 weeks, re-evaluate to confirm diagnosis. Safety of intermittent use for &gt;1 year has not been established, particularly since the effect on immune system development is unknown.</p></div>
<div class="block foc drugH1Div" id="F9564286"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Protopic: 0.03% (30 g [DSC], 60 g [DSC], 100 g [DSC]); 0.1% (30 g [DSC], 60 g [DSC], 100 g [DSC])</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 0.03% (30 g, 60 g, 100 g); 0.1% (30 g, 60 g, 100 g)</p></div>
<div class="block geq drugH1Div" id="F9559530"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F9564288"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Ointment</b> (Tacrolimus External)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.03% (per gram): $2.80 - $11.01</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">0.1% (per gram): $4.00 - $11.01</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52870373"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Ointment, External: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Protopic: 0.03% (30 g, 60 g, 100 g); 0.1% (30 g, 60 g, 100 g)</p></div>
<div class="block admp drugH1Div" id="F52614411"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">For external use only; avoid exposure to eyes or mouth. Wash hands before and after application. Use the smallest amount of ointment needed to control the signs and symptoms of atopic dermatitis. Do not cover with occlusive dressings. Do not bathe, shower, or swim right after application. Moisturizers can be applied after application. Limit sun exposure during the treatment period. Burning at the application site is most common in first few days; improves as atopic dermatitis improves.</p></div>
<div class="block adm drugH1Div" id="F9564232"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Topical: </b>Wash hands before and after application. Use the smallest amount of ointment needed to control symptoms. Use with occlusive dressings is not recommended; however, occlusion may be considered on photo-exposed areas in the treatment of nonfacial vitiligo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34160061']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34160061'])">Ref</a></span>). Do not bathe, shower, or swim right after application. Limit sun exposure during the treatment period. Limit application to involved areas.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral lichen planus (off-label use):</b> Apply a thin layer of tacrolimus using finger or cotton tip or a latex glove. Lesion should be dried before applying medication. Do not eat or drink for at least 30 minutes after application (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18269664','lexi-content-ref-18230389']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18269664','lexi-content-ref-18230389'])">Ref</a></span>).</p></div>
<div class="block hazard drugH1Div" id="F49132671"><span class="drugH1">Hazardous Drugs Handling Considerations</span>
<p style="text-indent:0em;">Hazardous agent (NIOSH 2016 [group 2]).</p>
<p style="text-indent:0em;margin-top:2em;">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>
<p style="text-indent:0em;margin-top:2em;">NIOSH recommends double gloving, a protective gown, and (if liquid that could splash) eye/face protection for administration of a topical product; if there is potential for inhalation, respiratory protection is recommended (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>
<div class="block sts drugH1Div" id="F9564184"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;margin-left:0em;text-align:justify;display:inline">Store at room temperature of 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block meg drugH1Div" id="F9559513"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=http%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FDrugSafety%2Fucm088996.pdf&amp;token=SHauxSdf9qNc6lLK16E8IL3aNdSXbSTKjKzr5jWxn%2F9%2Bevs591MjKrfB30zg8bRlhxfqCbSVcZt6Lesgs3QpOw%3D%3D&amp;TOPIC_ID=16050" target="_blank">http://www.fda.gov/downloads/Drugs/DrugSafety/ucm088996.pdf</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53570753"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of moderate to severe atopic dermatitis in immunocompetent patients not responsive to conventional therapy or when conventional therapy is not appropriate (second line) (Ointment 0.03%: FDA approved in ages ≥2 years and adults; Ointment 0.1%: FDA approved in ages ≥16 years and adults)</p></div>
<div class="block mst drugH1Div" id="F9559512"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Tacrolimus may be confused with everolimus, pimecrolimus, sirolimus, tamsulosin, temsirolimus</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F9564177"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F9564178"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the dermatologic adverse effect of Tacrolimus (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the immunosuppressive effect of Tacrolimus (Topical).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Moderate): May increase the serum concentration of Tacrolimus (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inhibitors (Strong): May increase the serum concentration of Tacrolimus (Topical).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Cytotoxic Chemotherapy): May enhance the immunosuppressive effect of Tacrolimus (Topical).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Miscellaneous Oncologic Agents): May enhance the immunosuppressive effect of Tacrolimus (Topical).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immunosuppressants (Therapeutic Immunosuppressant Agents): May enhance the immunosuppressive effect of Tacrolimus (Topical).<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: May enhance the immunosuppressive effect of Tacrolimus (Topical).<i> Risk X: Avoid combination</i></p></div>
<div class="block rep_considerations drugH1Div" id="F57574074"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Topical tacrolimus may be used for the treatment of atopic dermatitis and psoriasis in patients planning a pregnancy (AAD-NPF [Elmets 2021]; Vestergaard 2019).</p></div>
<div class="block pri drugH1Div" id="F9559535"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Tacrolimus crosses the human placenta following systemic use.</p>
<p style="text-indent:0em;margin-top:2em;">When preferred treatments are insufficient, topical tacrolimus may be used for the treatment of atopic dermatitis and psoriasis in pregnant patients (AAD-NPF [Elmets 2021]; Vestergaard 2019).</p>
<p style="text-indent:0em;margin-top:2em;">Also refer to the Tacrolimus (Systemic) monograph for additional information</p></div>
<div class="block pha drugH1Div" id="F9564194"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Suppresses cellular immunity (inhibits T-lymphocyte activation), by binding to an intracellular protein, FKBP-12 and complexes with calcineurin dependent proteins to inhibit calcineurin phosphatase activity</p></div>
<div class="block phk drugH1Div" id="F9564206"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Minimally absorbed; serum concentrations range from undetectable to 20 ng/mL (~2 ng/mL in majority of adult patients studied)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: ~0.5% </p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F12992812"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacroz | Tacroz forte</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacro Tic | Tacroderm</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacrolimus accord</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Atolimus | Dermus | Remus | Tacroderm | Tacrol | Tacrolim | Vitilimus</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Takrozem</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Atobach | Cropoc | Protopic | Tacrolimo | Tacroz | Tarfic</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cromidin | Proalid | Protopic | T inmun</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Cromus | Sineczem | T inmun</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacrolimus dermapharm | Takrozem</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Cromus | Protopic | Tacroz | Talgraf</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Cromus | T inmun | Tacroz</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Lebsanan</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tarolimus | Treczimus</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Cellmune | Takrozem</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacrolimus accord | Takrozem</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Takrozem</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Dermitopic | Protopic | Tacrolimus | Tacrolimus accord</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Remus</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Acroli | Atomus | Crolim | Crolimate | Crolin power | Eczrid | Eczrid forte | Hhmus | Imederm | Imograf | Laxoderm | Loprolif | Mustopic | Mylimus | Olix | Olmis | Pangraf | T Top | Tacel | Taclus | Tacmod | Tacoba forte | Tacoryza | Tacrimus | Tacro | Tacrofit | Tacrojon | Tacrokid | Tacromiz | Tacropure | Tacrotopic | Tacrotor | Tacroz | Tacsite | Tacvido | Tacvido forte | Takfa | Talimus | Tames forte | Tbis | Tecrosis | Tecrosis f | Topgraf</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Carelimus | Protopic | Takrozem</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Atopic | Protopic | Tacrus</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Eczemus | Remus | Rocimus | Tacrovate | Tacrovate forte | Tacroz forte | Tacrus | Talimus</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacro | Topicro</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacro Tic | Tacrus</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Lebsanan | Protopic</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Takrozem</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Arnaltem | Icralomidina | Limustin | Proalid | Protopic | Tenacrine | Traderma</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacrolimus accord | Takrozem</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Takrolimus accord | Takrozem</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Zematop</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Prodermic | Protopic | T inmun | Tacro Tic | Tacroz | Tacroz forte</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Rocimus | Tacroz</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Arilio | Crolimus | Eczemus | Eramus | Imunol | Prolimus | Romlus | Tacrocal | Tacrol | Tacrolim | Tacrozemus | Taczem | Topmus</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Dermitopic | Protopic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacrolimus cantabria | Takrozem</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">T inmun</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacroz | Tacroz Forte</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacropic</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacroz | Tacroz forte | Viotopic</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Takrolimus 2care4 | Takrolimus abacus medicine | Takrolimus accord | Takrolimus ebb | Takrozem</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Tacrolin | Topiclin</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacroli</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Eczemus | Tacroz | Tacroz forte</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Protopic | Tacroderm</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Cromus | Tacroz | Teinmun</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Imutac | Quantopic</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Protopic</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Talimus</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Tacroz forte</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-USP.1">
<a name="USP.1"></a>&lt;800&gt; Hazardous Drugs—Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary</i> (USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30252999">
<a name="30252999"></a>Abdul-Fattah B, Al-Muriesh M, Huang CZ. Efficacy of topical calcineurin inhibitors in pyoderma gangrenosum. <i>Dermatol Ther</i>. 2018;31(5):e12697. doi:10.1111/dth.12697<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/30252999/pubmed" id="30252999" target="_blank">30252999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20855912">
<a name="20855912"></a>Altieri M, Vaziri K, Orkin BA. Topical tacrolimus for parastomal pyoderma gangrenosum: a report of two cases. <i>Ostomy Wound Manage</i>. 2010;56(9):56-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/20855912/pubmed" id="20855912" target="_blank">20855912</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14699377">
<a name="14699377"></a>Bamford JT, Elliott BA, Haller IV. Tacrolimus effect on rosacea. <i>J Am Acad Dermatol</i>. 2004;50(1):107-108.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/14699377/pubmed" id="14699377" target="_blank">14699377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16781290">
<a name="16781290"></a>Belsito D, Wilson DC, Warshaw E, et al. A prospective randomized clinical trial of 0.1% tacrolimus ointment in a model of chronic allergic contact dermatitis. <i>J Am Acad Dermatol</i>. 2006;55(1):40-46. doi:10.1016/j.jaad.2006.03.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/16781290/pubmed" id="16781290" target="_blank">16781290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31408687">
<a name="31408687"></a>Chang HC, Hsu YP, Huang YC. The effectiveness of topical calcineurin inhibitors compared with topical corticosteroids in the treatment of vitiligo: a systematic review and meta-analysis. <i>J Am Acad Dermatol</i>. 2020;82(1):243-245. doi:10.1016/j.jaad.2019.07.108<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/31408687/pubmed" id="31408687" target="_blank">31408687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18269664">
<a name="18269664"></a>Corrocher G, Di Lorenzo G, Martinelli N, et al. Comparative effect of tacrolimus 0.1% ointment and clobetasol 0.05% ointment in patients with oral lichen planus. <i>J Clin Periodontol</i>. 2008;35(3):244-249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/18269664/pubmed" id="18269664" target="_blank">18269664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34342763">
<a name="34342763"></a>da Silva EL, de Lima TB, Rados PV, Visioli F. Efficacy of topical non-steroidal immunomodulators in the treatment of oral lichen planus: a systematic review and meta-analysis. <i>Clin Oral Investig</i>. 2021;25(9):5149-5169. doi:10.1007/s00784-021-04072-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/34342763/pubmed" id="34342763" target="_blank">34342763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19732254">
<a name="19732254"></a>Darsow U, Wollenberg A, Simon D, et al, "ETFAD/EADV Eczema Task Force 2009 Position Paper on Diagnosis and Treatment of Atopic Dermatitis," <i>J Eur Acad Dermatol Venereol</i>, 2010, 24(3):317-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/19732254/pubmed" id="19732254" target="_blank">19732254</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15313828">
<a name="15313828"></a>Ehst BD and Warshaw EM, “Alcohol-Induced Application Site Erythema After Topical Immunomodulator Use and Its Inhibition by Aspirin,” <i>Arch Dermatol</i>, 2004, 140(8):1014-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/15313828/pubmed" id="15313828" target="_blank">15313828</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34160061">
<a name="34160061"></a>Eleftheriadou V, Atkar R, Batchelor J, et al. British Association of Dermatologists guidelines for the management of people with vitiligo 2021. <i>Br J Dermatol.</i> 2022;186(1):18-29. doi:10.1111/bjd.20596<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/34160061/pubmed" id="34160061" target="_blank">34160061</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32738429">
<a name="32738429"></a>Elmets CA, Korman NJ, Prater EF, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. <i>J Am Acad Dermatol</i>. 2021;84(2):432-470. doi:10.1016/j.jaad.2020.07.087<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/32738429/pubmed" id="32738429" target="_blank">32738429</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18498336">
<a name="18498336"></a>Garg G, Thami GP. Clinical efficacy of tacrolimus in rosacea. <i>J Eur Acad Dermatol Venereol</i>. 2009;23(2):239-240.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/18498336/pubmed" id="18498336" target="_blank">18498336</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15149540">
<a name="15149540"></a>Ghislain PD, De Decker I, Lachapelle JM. Efficacy and systemic absorption of topical tacrolimus used in pyoderma gangrenosum. <i>Br J Dermatol</i>. 2004;150(5):1052-1053.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/15149540/pubmed" id="15149540" target="_blank">15149540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25070257">
<a name="25070257"></a>Han JS, Won KH, Chang SE, Kim JE. Tacrolimus 0.1% ointment in the treatment of allergic contact dermatitis: a new approach. <i>Int J Dermatol</i>. 2014;53(10):e470-e471. doi:10.1111/ijd.12641<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/25070257/pubmed" id="25070257" target="_blank">25070257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28244094">
<a name="28244094"></a>Johnston GA, Exton LS, Mohd Mustapa MF, et al. British Association of Dermatologists' guidelines for the management of contact dermatitis 2017. <i>Br J Dermatol</i>. 2017;176(2):317-329. doi:10.1111/bjd.15239<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/28244094/pubmed" id="28244094" target="_blank">28244094</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19207676">
<a name="19207676"></a>Katsarou A, Armenaka M, Vosynioti V, et al. Tacrolimus ointment 0.1% in the treatment of allergic contact eyelid dermatitis. <i>J Eur Acad Dermatol Venereol</i>. 2009;23(4):382-387. doi:10.1111/j.1468-3083.2008.03056.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/19207676/pubmed" id="19207676" target="_blank">19207676</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16710580">
<a name="16710580"></a>Laeijendecker R, Tank B, Dekker SK, Neumann HA. A comparison of treatment of oral lichen planus with topical tacrolimus and triamcinolone acetonide ointment. <i>Acta Derm Venereol</i>. 2006;86(3):227-229.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/16710580/pubmed" id="16710580" target="_blank">16710580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15523350">
<a name="15523350"></a>Lebwohl M, Freeman AK, Chapman MS, Feldman SR, Hartle JE, Henning A; Tacrolimus Ointment Study Group. Tacrolimus ointment is effective for facial and intertriginous psoriasis. <i>J Am Acad Dermatol</i>. 2004;51(5):723-730. doi:10.1016/j.jaad.2004.07.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/15523350/pubmed" id="15523350" target="_blank">15523350</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31141108">
<a name="31141108"></a>Lee JH, Kwon HS, Jung HM, et al. Treatment outcomes of topical calcineurin inhibitor therapy for patients with vitiligo: a systematic review and meta-analysis. <i>JAMA Dermatol</i>. 2019;155(8):929-938. doi:10.1001/jamadermatol.2019.0696<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/31141108/pubmed" id="31141108" target="_blank">31141108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15616208">
<a name="15616208"></a>Lubbe J and Milingou M, “Images in Clinical Medicine. Tacrolimus Ointment, Alcohol, and Facial Flushing,” <i>N Engl J Med</i>, 2004, 351(26):2740.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/15616208/pubmed" id="15616208" target="_blank">15616208</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12171681">
<a name="12171681"></a>Lyon CC, Stapleton M, Smith AJ, et al. Topical tacrolimus in the management of peristomal pyoderma gangrenosum. <i>J Dermatolog Treat</i>. 2001;12(1):13-17.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/12171681/pubmed" id="12171681" target="_blank">12171681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20831696">
<a name="20831696"></a>Majid I. Does topical tacrolimus ointment enhance the efficacy of narrowband ultraviolet B therapy in vitiligo? A left-right comparison study. <i>Photodermatol Photoimmunol Photomed</i>. 2010;26(5):230-234.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/20831696/pubmed" id="20831696" target="_blank">20831696</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21466589">
<a name="21466589"></a>Nordal EJ, Guleng GE, Rönnevig JR. Treatment of vitiligo with narrowband-UVB (TL01) combined with tacrolimus ointment (0.1%) vs. placebo ointment, a randomized right/left double-blind comparative study. <i>J Eur Acad Dermatol Venereol</i>. 2011;25(12):1440-1443. doi:10.1111/j.1468-3083.2011.04002.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/21466589/pubmed" id="21466589" target="_blank">21466589</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Protopic.1">
<a name="Protopic.1"></a>Protopic (tacrolimus) [prescribing information]. Madison, NJ: LEO Pharma Inc.; February 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19496898">
<a name="19496898"></a>Radakovic S, Breier-Maly J, Konschitzky R, et al. Response of vitiligo to once- vs. twice-daily topical tacrolimus: a controlled prospective, randomized, observer-blinded trial. <i>J Eur Acad Dermatol Venereol</i>. 2009;23(8):951-953.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/19496898/pubmed" id="19496898" target="_blank">19496898</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18230389">
<a name="18230389"></a>Radfar L, Wild RC, Suresh L. A comparative treatment study of topical tacrolimus and clobetasol in oral lichen planus. <i>Oral Surg Oral Med Oral Pathol Oral Radiol Endod</i>. 2008;105(2):187-193.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/18230389/pubmed" id="18230389" target="_blank">18230389</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31100992">
<a name="31100992"></a>Reynolds KA, Pithadia DJ, Lee EB, Wu JJ. Treatments for inverse psoriasis: a systematic review. <i>J Dermatolog Treat</i>. 2020;31(8):786-793. doi:10.1080/09546634.2019.1620912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/31100992/pubmed" id="31100992" target="_blank">31100992</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16140675">
<a name="16140675"></a>Schachner LA, Lamerson C, Sheehan MP, et al, "Tacrolimus Ointment 0.03% is Safe and Effective for the Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients: Results From a Randomized, Double-Blind, Vehicle-Controlled Study," <i>Pediatrics</i>, 2005, 116(3):e334-42.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/16140675/pubmed" id="16140675" target="_blank">16140675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23374261">
<a name="23374261"></a>Schneider L, Tilles S, Lio P, et al. Atopic dermatitis: a practice parameter update 2012<b>. </b>
<i>J Allergy Clin Immunol.</i> 2013;131(2):295-299.e1-27. doi: 10.1016/j.jaci.2012.12.672.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/23374261/pubmed" id="23374261" target="_blank">23374261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23067089">
<a name="23067089"></a>Sonthalia S, Singal A. Comparative efficacy of tacrolimus 0.1% ointment and clobetasol propionate 0.05% ointment in oral lichen planus: a randomized double-blind trial. <i>Int J Dermatol</i>. 2012;51(11):1371-1378.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/23067089/pubmed" id="23067089" target="_blank">23067089</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19651562">
<a name="19651562"></a>Stinco G, Piccirillo F, Forcione M, Valent F, Patrone P. An open randomized study to compare narrow band UVB, topical pimecrolimus and topical tacrolimus in the treatment of vitiligo. <i>Eur J Dermatol</i>. 2009;19(6):588-593. doi:10.1684/ejd.2009.0779<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/19651562/pubmed" id="19651562" target="_blank">19651562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34133803">
<a name="34133803"></a>Su Z, Hu J, Cheng B, Tao X. Efficacy and safety of topical administration of tacrolimus in oral lichen planus: an updated systematic review and meta-analysis of randomized controlled trials. <i>J Oral Pathol Med</i>. 2022;51(1):63-73. doi:10.1111/jop.13217<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/34133803/pubmed" id="34133803" target="_blank">34133803</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22860621">
<a name="22860621"></a>Taieb A, Alomar A, Böhm M, et al; Vitiligo European Task Force (VETF); European Academy of Dermatology and Venereology (EADV); Union Européenne des Médecins Spécialistes (UEMS). Guidelines for the management of vitiligo: the European Dermatology Forum consensus. <i>Br J Dermatol</i>. 2013;168(1):5-19. doi:10.1111/j.1365-2133.2012.11197.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/22860621/pubmed" id="22860621" target="_blank">22860621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-HHS.1">
<a name="HHS.1"></a>US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href="https://www.cdc.gov/niosh/docs/2016-161/default.html" target="_blank">https://www.cdc.gov/niosh/docs/2016-161/default.html</a>. Updated September 2016. Accessed October 5, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31231864">
<a name="31231864"></a>Vestergaard C, Wollenberg A, Barbarot S, et al. European task force on atopic dermatitis position paper: treatment of parental atopic dermatitis during preconception, pregnancy and lactation period. <i>J Eur Acad Dermatol Venereol.</i> 2019;33(9):1644-1659. doi:10.1111/jdv.15709<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/tacrolimus-topical-pediatric-drug-information/abstract-text/31231864/pubmed" id="31231864" target="_blank">31231864</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 16050 Version 261.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
